急性冠脉综合征PCI术后β受体阻滞剂与死亡率的关系
平均随访5.3±3.5年,83.3%患者使用β受体阻滞剂,其死亡率较低(13.1% vs 19.5%,p=0.0001),多变量Cox模型显示β受体阻滞剂与较低全因死亡率相关(调整HR 0.87,95%CI 0.78-0.97,p=0.014)。亚组分析中,LVEF<35%和35%-50%患者获益,LVEF>50%患者无获益。
要点
- ACS患者PCI术后30天β受体阻滞剂使用率高(83.3%),与较低全因死亡率相关。
- LVEF<35%和LVEF 35%-50%患者使用β受体阻滞剂与死亡率降低相关。
- LVEF>50%患者使用β受体阻滞剂与死亡率无显著关联。
核心结论
- PCI术后β受体阻滞剂使用率仍高,且与全因死亡率降低相关。
- 死亡率降低主要见于射血分数降低的患者,而非射血分数保留的患者。
研究设计与样本
- 利用大型PCI注册研究,分析2005年1月至2017年6月因ACS行PCI且30天存活的患者数据。
- 比较30天时使用与未使用β受体阻滞剂的患者,主要结局为全因死亡率,平均随访5.3±3.5年。
主要发现
- β受体阻滞剂组死亡率为13.1%,非β受体阻滞剂组为19.5%(p=0.0001)。
- 多变量Cox比例风险模型显示,β受体阻滞剂使用与较低总体死亡率相关(调整HR 0.87,95%CI 0.78-0.97,p=0.014)。
- 亚组分析:LVEF<35%患者调整HR 0.63(95%CI 0.44-0.91,p=0.013);LVEF 35%-50%患者调整HR 0.80(95%CI 0.68-0.95,p=0.01);LVEF>50%患者调整HR 1.03(95%CI 0.87-1.21,p=0.74)。
临床怎么用
- 对于ACS行PCI术后30天存活的患者,尤其是LVEF降低者,使用β受体阻滞剂与死亡率降低相关。
- LVEF保留的患者使用β受体阻滞剂未显示死亡率获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: There is a paucity of evidence supporting routine beta blocker (BB) use in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). The aim of this study was to evaluate BB use post PCI and its association with mortality. Furthermore, the study aimed to evaluate the association between BB and mortality in the subgroups of patients with left ventricular ejection fraction (LVEF) <35%, LVEF 35%-50% and LVEF >50%. METHODS: Using a large PCI registry, data from patients with ACS between January 2005 and June 2017 who were alive at 30 days were analysed. Those patients taking BB at 30 days were compared with those who were not taking BB. The primary outcome was all-cause mortality. The mean follow-up was 5.3±3.5 years. RESULTS: Of the 17 562 patients, 83.3% were on BB. Mortality was lower in the BB group (13.1% vs 19.5%, p=0.0001). Multivariable Cox proportional hazards model showed that BB use was associated with lower overall mortality (adjusted HR 0.87, 95% CI 0.78 to 0.97, p=0.014). In the subgroup analysis, BB use was associated with reduced mortality in LVEF <35% (adjusted HR 0.63, 95% CI 0.44 to 0.91, p=0.013), LVEF 35%-50% (adjusted HR 0.80, 95% CI 0.68 to 0.95, p=0.01), but not LVEF >50% (adjusted HR 1.03, 95% CI 0.87 to 1.21, p=0.74). CONCLUSION: BB use remains high and is associated with reduced mortality. This reduction in mortality is primarily seen in those with reduced ejection fraction, but not in those with preserved ejection fraction.
引用
- Peck KY, Andrianopoulos N, Dinh D, et al. Role of beta blockers following percutaneous coronary intervention for acute coronary syndrome. Heart. 2020. PMID: 32887736. doi:10.1136/heartjnl-2020-316605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。